GT Biopharma Inc. announced several changes to its board of directors. On May 7, 2025, Hilary Kramer was appointed as a non-employee director, and Bruce Wendel resigned from the board. The following day, Andrew Ritter was also appointed as a non-employee director. On May 12, 2025, Rajesh Shrotriya resigned, and the board decided to reduce the number of directors from six to four. Ms. Kramer will chair the Nominating Committee, while Mr. Ritter will chair the Compensation Committee. Both have been deemed independent per Nasdaq's listing requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.